Are there any patients taking Tazemetostat who are ineffective?

Patients taking tazemetostat may experience failure to respond to treatment. Although tazerestat is used to treat a specific type of malignancy, follicular lymphoma (FL) and epithelioid sarcoma (ES), the effectiveness of treatment may vary among individuals. Everyone's physical condition and disease status are different, so tazerestat may not be effective or less effective in some patients.

Tazerestat is a first-in-class, selective oral enhancer inhibitor of zester homolog 2 (EZH2), a histone methyltransferase that is mutated in approximately one-quarter of follicular lymphoma cases. Although most patients respond to initial treatment, many patients experience disease progression with progressively shorter intervals between subsequent treatments. The success of a treatment regimen may be affected by a variety of factors, including the patient's genotype, tumor type, and clinical status. Before using tazerestat, doctors usually evaluate each patient's specific situation and consider whether this drug is appropriate. If the treatment is ineffective, the doctor may adjust the treatment plan or try other treatments based on the actual situation.

The original drug of tazerestat is not yet available in the domestic market and is therefore not included in medical insurance. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.